Researchers Identify Male Pattern Baldness Inhibitor

Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified an abnormal amount of the protein Prostaglandin D2 in the bald spots of men suffering from male pattern baldness. The discovery can lead to new treatments for the most common cause of hair loss in men.

The researchers found that the prostaglandin known as PGD2 and its derivative 15-dPGJ2 inhibit hair growth. The inhibition occurs via the receptor called GPR44. This could be the target for future treatments for androgenetic alopecia in both men and women with thinning or hair loss.

Male pattern baldness occurs in 8 out of 10 men under the age of 70 years old. It causes the hair follicles to reduce in size and produce microscopic hairs. These grow for a shorter duration of time compared to normal follicles.

Researchers scanned for potential biological causes of baldness by looking at scalp tissues from blading and non-bald spots. Then they compared the findings in mouse models. They found out that the levels of PGD2 were higher in bald scalp tissue than what is found in normal scalp.

Prostaglandins are known for their role in various body functions, such as controlling cell growth, dilating smooth muscle tissue and constricting them as well. Researchers discovered that PGD2 inhibits hair growth.